365 related articles for article (PubMed ID: 29322204)
1. Evolving notions on immune response in colorectal cancer and their implications for biomarker development.
Grizzi F; Basso G; Borroni EM; Cavalleri T; Bianchi P; Stifter S; Chiriva-Internati M; Malesci A; Laghi L
Inflamm Res; 2018 May; 67(5):375-389. PubMed ID: 29322204
[TBL] [Abstract][Full Text] [Related]
2. Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope?
Grizzi F; Celesti G; Basso G; Laghi L
World J Gastroenterol; 2012 Dec; 18(45):6532-6. PubMed ID: 23236225
[TBL] [Abstract][Full Text] [Related]
3. Immune classification of colorectal cancer patients: impressive but how complete?
Baxevanis CN; Papamichail M; Perez SA
Expert Opin Biol Ther; 2013 Apr; 13(4):517-26. PubMed ID: 23289642
[TBL] [Abstract][Full Text] [Related]
4. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
6. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
Yörüker EE; Holdenrieder S; Gezer U
Clin Chim Acta; 2016 Apr; 455():26-32. PubMed ID: 26797671
[TBL] [Abstract][Full Text] [Related]
7. [Immune response and digestive cancers: Prognostic and therapeutic implications].
Bibeau F; Bazille C; Svrcek M; Pierson R; Lagorce-Pagès C; Cohen R; André T
Ann Pathol; 2017 Feb; 37(1):111-116. PubMed ID: 28111038
[TBL] [Abstract][Full Text] [Related]
8. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?
Rossi S; Basso M; Strippoli A; Schinzari G; D'Argento E; Larocca M; Cassano A; Barone C
Clin Colorectal Cancer; 2017 Dec; 16(4):264-274. PubMed ID: 28412137
[TBL] [Abstract][Full Text] [Related]
9. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
10. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
11. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.
Ohta M; Tanaka F; Yamaguchi H; Sadanaga N; Inoue H; Mori M
Int J Oncol; 2005 Jan; 26(1):41-7. PubMed ID: 15586223
[TBL] [Abstract][Full Text] [Related]
12. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.
Roelands J; Kuppen PJK; Vermeulen L; Maccalli C; Decock J; Wang E; Marincola FM; Bedognetti D; Hendrickx W
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064420
[TBL] [Abstract][Full Text] [Related]
13. Telomeres and telomerase in the clinical management of colorectal cancer.
Piñol-Felis C; Fernández-Marcelo T; Viñas-Salas J; Valls-Bautista C
Clin Transl Oncol; 2017 Apr; 19(4):399-408. PubMed ID: 27761787
[TBL] [Abstract][Full Text] [Related]
14. Staging of colorectal cancer using lipid biomarkers and machine learning.
Krishnan ST; Winkler D; Creek D; Anderson D; Kirana C; Maddern GJ; Fenix K; Hauben E; Rudd D; Voelcker NH
Metabolomics; 2023 Sep; 19(10):84. PubMed ID: 37731020
[TBL] [Abstract][Full Text] [Related]
15. Cancer Stem Cells and Molecular Biology Test in Colorectal Cancer: Therapeutic Implications.
Effendi-Ys R
Acta Med Indones; 2017 Oct; 49(4):351-359. PubMed ID: 29348387
[TBL] [Abstract][Full Text] [Related]
16. Novel prognostic biomarkers in colorectal cancer.
Malesci A; Laghi L
Dig Dis; 2012; 30(3):296-303. PubMed ID: 22722555
[TBL] [Abstract][Full Text] [Related]
17. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
Atreya I; Neurath MF
Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Biomarkers in Colorectal Cancer.
Verma M; Kumar V
Mol Diagn Ther; 2017 Apr; 21(2):153-165. PubMed ID: 27878475
[TBL] [Abstract][Full Text] [Related]
19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
